V

Varian

Tech-enabled radiation oncology hardware and software

Global Marketing Manager - Atellica Assays, Infectious Disease

Full-Time
$137.9k - $189.6k
Senior
Bachelor's, MBA
Remote in USA
RemoteTravel up to 10%.
Growth & MarketingProduct Marketing
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • At least 5 years of progressive marketing, product management, or commercial experience in in-vitro diagnostics, laboratory medicine, or a closely related diagnostics space.
  • Experience contributing to portfolio strategy, product development, global or regional launches, and post-launch growth.
  • Ability to turn complex clinical and technical information into clear customer value propositions and effective commercial tools.
  • Demonstrated success leading work across functions and influencing stakeholders without direct authority.
Responsibilities
  • Develop the global strategy for assigned Atellica Infectious Disease assays from opportunity assessment and product definition through launch, growth, and lifecycle management.
  • Assess market potential, customer needs, competitive dynamics, and portfolio performance to recommend priorities, investments, and product enhancements.
  • Build understanding of Infectious Disease testing needs across laboratories, health systems, and other relevant stakeholders.
  • Gather voice-of-customer and regional insights, identify unmet needs, and translate them into product requirements, market opportunities, and differentiated value propositions.
  • Partner with R&D, Medical Affairs, Regulatory, Quality, and regional teams to inform product requirements, evidence needs, claims, and launch plans.
  • Represent the market and customer perspective at development and portfolio decision points and help teams resolve trade-offs that affect customer value and commercial success.
  • Lead global positioning, messaging, launch planning, and readiness for assigned assays.
  • Develop customer-facing content, sales tools, training, and campaign strategies that regional teams can adapt to their markets.
  • Coordinate across assays, analyzers, automation, and informatics to present a clear, integrated customer offering.
  • Monitor competitor portfolios, testing practices, and market trends.
  • Develop competitive selling guidance and support pricing and value discussions.
  • Track launch performance, adoption, and customer feedback; use those insights to refine plans and identify growth opportunities.
Desired Qualifications
  • Experience with infectious disease assays, immunoassay, or core laboratory diagnostics.
  • Experience developing market assessments, business cases, pricing recommendations, or product forecasts.
  • Global or international marketing experience, including collaboration with regional commercial teams.
  • An MBA or advanced degree in business, life sciences, or a related discipline.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • 401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.